Compare Halliburton Company (HAL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs ResMed Inc. — how do they compare? Halliburton Company trades at $32.44 (market cap $26.45B), while ResMed Inc. trades at $227.51 (market cap $31.78B). The key difference: ResMed Inc. is the larger of the two by market cap, and Halliburton Company pays the higher dividend (2.14%). Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and ResMed Inc. for 51 Days on average.
| HAL | RMD | |
|---|---|---|
Market Cap | $26.45B | $31.78B |
Volume | 11,229,274 | 1,128,382 |
Sector | Energy | Health |
52-Week High | $42.98 | $277.88 |
52-Week Low | $21.82 | $182.82 |
Typical Hold Time | 89 Days | 51 Days |
Enterprise Value | $32.60B | $31.14B |
Dividend Yield | 2.14% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.57, down 0.46% on the day, amid a bearish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights expansion in Venezuela and a major contract win in Cyprus, signaling growth initiatives. Financials show solid profitability with a net income margin of 7.16% and a P/E ratio of 16.62, though 2025 revenue dipped slightly to $22.18 billion.
The outlook is supported by strong analyst consensus with a $43.11 price target and 73% buy ratings, but risks include oil price volatility and execution challenges in new markets. Cash flow trends have been mixed, with 2025 net cash flow negative $412 million, though 2026 projects a return to positive territory.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
